{"id":"rfviii-bay81-8973-on-demand","safety":{"commonSideEffects":[{"rate":"null","effect":"Inj site reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297873","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"rFVIII (BAY81-8973) works by replacing the deficient or defective factor VIII protein in patients with hemophilia A, allowing for proper blood clotting and preventing excessive bleeding. This recombinant protein is designed to have a similar structure and function to the natural factor VIII protein, making it an effective treatment option for patients with this condition.","oneSentence":"rFVIII (BAY81-8973) is a recombinant factor VIII replacement therapy that mimics the natural protein to treat bleeding episodes in patients with hemophilia A.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:55.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"On-demand treatment of bleeding episodes in patients with hemophilia A"}]},"trialDetails":[{"nctId":"NCT01233258","phase":"PHASE3","title":"A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01","conditions":"Hemophilia A","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rFVIII (BAY81-8973) on demand","genericName":"rFVIII (BAY81-8973) on demand","companyName":"Bayer","companyId":"bayer","modality":"Biologic","firstApprovalDate":"","aiSummary":"rFVIII (BAY81-8973) is a recombinant factor VIII replacement therapy that mimics the natural protein to treat bleeding episodes in patients with hemophilia A. Used for On-demand treatment of bleeding episodes in patients with hemophilia A.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}